(Q28165358)

4

object named as

Håkan Emanuelsson

0 references

W. Douglas Weaver

3

object named as

W Douglas Weaver

0 references

Anders Bylock

7

object named as

Anders Bylock

0 references

author name string

Robert G Wilcox

2

0 references

Andrew Goodvin

5

0 references

Per Nyström

Antithrombotic agents in coronary artery disease

6

0 references

language of work or name

English

0 references

publication date

6 September 2003

0 references

published in

The Lancet

0 references

volume

362

0 references

issue

9386

0 references

page(s)

789-97

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

ACC/AHA Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction--2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice G

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Management of acute myocardial infarction in patients presenting with ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Reactivation of unstable angina after the discontinuation of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction—the ASSENT Plus study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Warfarin, aspirin, or both after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914287-0

7 January 2021

10.1016/S0140-6736(03)14287-0

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

13678873

1 reference

Consolidated OpenCitations Corpus – April 2017